Tetrous® Achieves Prestigious 'Most Exciting New Product' Award at Shoulder 360™
Tetrous, Inc. continues to carve out a prominent niche in the field of orthopedic sports medicine with its recent accolade, being awarded 'Most Exciting New Product' at the revered Shoulder 360™ conference. This recognition comes on the heels of their earlier triumph at the AOSSM Annual Meeting, where they received the ACE (Advancing Cutting-Edge) Award in 2024 for their groundbreaking technologies. The Shoulder 360 event is a crucial platform for healthcare professionals specializing in shoulder disorders, enabling collaboration and education regarding advancements in treatment and care.
This latest award highlights the effectiveness of Tetrous' EnFix® product line, which includes notable offerings like EnFix RC®, EnFix TAC-O®, EnFix TAC-T®, and EnFix ACL™. These products are meticulously designed to tackle persistent challenges associated with orthopedic soft tissue repairs, particularly in critical procedures such as rotator cuff repairs, which often experience alarmingly high failure rates. The core principle guiding Tetrous in its innovation is the restoration of the bone-to-tendon interface—referred to as the enthesis—pivotal for successful healing and recovery.
Central to Tetrous’ offerings is its unique demineralized bone fiber (DBF) implant, tailored exclusively for the anatomical nuances of the bone-tendon junction, providing robust biological factors essential for effective repair. By strategically removing the mineral elements from allograft bone, crucial growth factors are unveiled, which actively promote the formation of new tissues essential for recovery. The EnFix product's innovative peg design facilitates direct implantation into the bone at the repair site, which, paired with an internal cannulation feature, enables bone marrow cells to effectively engage with the implant, triggering the healing process.
Since its last notable award, Tetrous has reported impressive advancements both commercially and clinically. They have successfully expanded their reach, now engaging over 100 surgeon users, showcasing a remarkable threefold increase in the year-on-year uptake of their products. The company surpassed the milestone of 3,500 implanted devices, underscoring strong clinical adoption of their innovative solutions. Moreover, the clinical application of the EnFix line has broadened to various anatomical entheses and has included the successful completion of its first procedures involving the EnFix ACL for Anterior Cruciate Ligament (ACL) repairs. Additionally, Tetrous has expanded its international distribution, establishing active markets in the United States, Australia, and New Zealand, while also eyeing new opportunities in Taiwan.
Dr. Raffy Mirzayan, Co-Founder of Shoulder 360, voices the professional community’s recognition by declaring, "Shoulder360 was proud to award the 'Most Exciting New Product/Service Award' for 2026 to Tetrous. The award is a honor voted on by surgeon attendees, and Tetrous' commitment to enhancing enthesis healing through its innovative EnFix product line truly set them apart."
John Bojanowski, the Director and Chief Commercial Officer at Tetrous, shared insights into the accelerating momentum behind their innovations, stating, "The rapid pace of adoption we've witnessed has been incredibly encouraging. Surpassing 3,500 implants and expanding internationally signifies that the surgical community recognizes the immense value Tetrous brings to operating rooms across the globe."
The growing confidence among surgeons is significant, as noted by Bradley Patt, PhD, Co-founder and CEO of Tetrous. He articulated that their recognition at the Shoulder 360 event represents the medical community’s acknowledgement of their differentiated solutions, crucial for achieving optimal healing through a holistic approach that encompasses (a) fixation, (b) structure, and now importantly, (c) biology. This triadic methodology aims to yield superior outcomes for patients now and in the future.
Tetrous, Inc. commenced its operations in 2019 with a commitment to pioneering technologies for enthesis repair within the domain of sports medicine. Their EnFix series, which includes EnFix RC®, EnFix TAC®, and EnFix ACL™, is engineered to improve natural healing responses by fostering biological regeneration at the critical junction where bone meets tendon. By emphasizing clinically validated technologies that mitigate failure rates, expedite recovery, and restore functionalities, Tetrous strives to deliver consistent, evidence-based results that significantly improve both immediate patient recovery times and long-term health outcomes.
The company enjoys robust Intellectual Property protection for its EnFix product line, featuring multiple issued patents and an exclusive licensing agreement for its demineralized bone fiber technology, sourced from TheraCell, an ISTO Biologics Company. Tetrous, Inc. is positioned to continue making strides in orthopedic sports medicine, as evidenced by their recent accolades and innovative product offerings.
This latest award highlights the effectiveness of Tetrous' EnFix® product line, which includes notable offerings like EnFix RC®, EnFix TAC-O®, EnFix TAC-T®, and EnFix ACL™. These products are meticulously designed to tackle persistent challenges associated with orthopedic soft tissue repairs, particularly in critical procedures such as rotator cuff repairs, which often experience alarmingly high failure rates. The core principle guiding Tetrous in its innovation is the restoration of the bone-to-tendon interface—referred to as the enthesis—pivotal for successful healing and recovery.
Central to Tetrous’ offerings is its unique demineralized bone fiber (DBF) implant, tailored exclusively for the anatomical nuances of the bone-tendon junction, providing robust biological factors essential for effective repair. By strategically removing the mineral elements from allograft bone, crucial growth factors are unveiled, which actively promote the formation of new tissues essential for recovery. The EnFix product's innovative peg design facilitates direct implantation into the bone at the repair site, which, paired with an internal cannulation feature, enables bone marrow cells to effectively engage with the implant, triggering the healing process.
Since its last notable award, Tetrous has reported impressive advancements both commercially and clinically. They have successfully expanded their reach, now engaging over 100 surgeon users, showcasing a remarkable threefold increase in the year-on-year uptake of their products. The company surpassed the milestone of 3,500 implanted devices, underscoring strong clinical adoption of their innovative solutions. Moreover, the clinical application of the EnFix line has broadened to various anatomical entheses and has included the successful completion of its first procedures involving the EnFix ACL for Anterior Cruciate Ligament (ACL) repairs. Additionally, Tetrous has expanded its international distribution, establishing active markets in the United States, Australia, and New Zealand, while also eyeing new opportunities in Taiwan.
Dr. Raffy Mirzayan, Co-Founder of Shoulder 360, voices the professional community’s recognition by declaring, "Shoulder360 was proud to award the 'Most Exciting New Product/Service Award' for 2026 to Tetrous. The award is a honor voted on by surgeon attendees, and Tetrous' commitment to enhancing enthesis healing through its innovative EnFix product line truly set them apart."
John Bojanowski, the Director and Chief Commercial Officer at Tetrous, shared insights into the accelerating momentum behind their innovations, stating, "The rapid pace of adoption we've witnessed has been incredibly encouraging. Surpassing 3,500 implants and expanding internationally signifies that the surgical community recognizes the immense value Tetrous brings to operating rooms across the globe."
The growing confidence among surgeons is significant, as noted by Bradley Patt, PhD, Co-founder and CEO of Tetrous. He articulated that their recognition at the Shoulder 360 event represents the medical community’s acknowledgement of their differentiated solutions, crucial for achieving optimal healing through a holistic approach that encompasses (a) fixation, (b) structure, and now importantly, (c) biology. This triadic methodology aims to yield superior outcomes for patients now and in the future.
Tetrous, Inc. commenced its operations in 2019 with a commitment to pioneering technologies for enthesis repair within the domain of sports medicine. Their EnFix series, which includes EnFix RC®, EnFix TAC®, and EnFix ACL™, is engineered to improve natural healing responses by fostering biological regeneration at the critical junction where bone meets tendon. By emphasizing clinically validated technologies that mitigate failure rates, expedite recovery, and restore functionalities, Tetrous strives to deliver consistent, evidence-based results that significantly improve both immediate patient recovery times and long-term health outcomes.
The company enjoys robust Intellectual Property protection for its EnFix product line, featuring multiple issued patents and an exclusive licensing agreement for its demineralized bone fiber technology, sourced from TheraCell, an ISTO Biologics Company. Tetrous, Inc. is positioned to continue making strides in orthopedic sports medicine, as evidenced by their recent accolades and innovative product offerings.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.